Exiqon enters licence agreement with IDT  

2004.01.07
The Danish biotech company has entered a licence agreement with US based Integrated DNA Technologies concerning Exiqon's LNA technology

Biotech company Exiqon has entered a licence agreement with US based Integrated DNA Technologies (IDT) concerning Exiqon's Locked Nucleic Acid (LNA) technology. The agreement gives IDT the right to produce and sell LNA oligonucleotides for genomic research. Exiqon MD Lars Kongsbak says the agreement with IDT is an important step in Exiqon's strategy to commercialise its LNA technology.

 

Exiqon was founded in 1996 and is based in Vedbæk north of Copenhagen. Since 1996 the company has raised DKK 170 million (USD 28.9 million) from investors including Scandinavian Life Science Venture, Teknoinvest, Nobel Group and the Employees Capital Pension Fund. The news is reported by BioTechDenmark online.

 

Link > Exiqon

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×